UiPath (NYSE:PATH) Price Target Increased to $15.00 by Analysts at Wells Fargo & Company

UiPath (NYSE:PATH) had its target price raised by Wells Fargo & Company from $14.00 to $15.00 in a research report sent to investors on Friday morning, Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the healthcare company’s stock.

Several other research firms have also recently weighed in on PATH. Canaccord Genuity Group cut their price objective on UiPath from $30.00 to $19.00 and set a buy rating on the stock in a report on Friday, May 31st. JPMorgan Chase & Co. cut their price objective on UiPath from $28.00 to $19.00 and set an overweight rating on the stock in a report on Thursday, May 30th. William Blair cut UiPath from an outperform rating to a market perform rating in a report on Thursday, May 30th. DA Davidson dropped their target price on UiPath from $24.00 to $13.00 and set a neutral rating on the stock in a research report on Thursday, May 30th. Finally, Scotiabank dropped their target price on UiPath from $30.00 to $25.00 and set a sector perform rating on the stock in a research report on Wednesday, May 29th. Sixteen research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of Hold and an average price target of $17.71.

UiPath Trading Up 1.8 %

Shares of PATH opened at $12.19 on Friday. UiPath has a 1 year low of $10.37 and a 1 year high of $27.87. The stock has a market cap of $6.98 billion, a P/E ratio of -76.19 and a beta of 0.87. The stock’s 50-day moving average price is $12.19 and its two-hundred day moving average price is $16.54.

UiPath (NYSE:PATH) last released its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 3.89% and a negative net margin of 8.13%. The business had revenue of $316.00 million for the quarter, compared to analysts’ expectations of $303.69 million. During the same quarter in the previous year, the business posted ($0.09) EPS. UiPath’s revenue for the quarter was up 10.0% on a year-over-year basis. As a group, equities analysts forecast that UiPath will post -0.22 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mark Sheptoff Financial Planning LLC bought a new position in shares of UiPath during the 4th quarter worth approximately $25,000. ORG Partners LLC boosted its stake in shares of UiPath by 875.6% during the 1st quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after acquiring an additional 1,112 shares during the period. Hantz Financial Services Inc. bought a new position in shares of UiPath during the 2nd quarter worth approximately $28,000. Redwood Wealth Management Group LLC bought a new position in shares of UiPath during the 2nd quarter worth approximately $43,000. Finally, Lindbrook Capital LLC boosted its stake in shares of UiPath by 46.0% during the 1st quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after acquiring an additional 639 shares during the period. 62.50% of the stock is currently owned by institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.